Trichostatin A (TSA)

Catalog No.S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Size Price Stock Quantity  
In DMSO USD 324 In stock
USD 247 In stock
USD 447 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • Effect of TSA, SAHA and silibinin alone and in combination on left panel: IF staining for p-histone H3 Ser 10 and p-MPM-2 Ser /Thr positive cells and a-tubulin for mitotic spindle and DAPI as nuclear stain in H1299 cells. Right panel: % positive p-histone H3 Ser 10 mitotic cells and expression of p-MPM-2 Ser /Thr protein levels in H1299 cells.

    Epigenetics 2012 7(10):1161-72. Trichostatin A (TSA) purchased from Selleck.

    (B) The mRNA level of PRRT2 in the presence of different concentrations of DAC and TSA.

    Biochem Biophys Res Commun, 2017, 485(2):454-460. Trichostatin A (TSA) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

  • Western blot analysis of Acetyl-H3 and H3. 0-20μM TSA was added.

     

     

    2010 Dr. Zhang of Tianjin Medical University. Trichostatin A (TSA) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Targets
HDAC [1]
(Cell-free assay)
~1.8 nM
In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 MV\GeY5kfGmxbjDBd5NigQ>? MlHyNE44|ryP NYP6TIhPOjSq NWTaZ5RK\XSqYX7vcC=> NITtbIRmdmijbnPld{BGVmGFIHHj[ZR6dGG2aX;uJIFv\CCrbnPy[YF{\XNiRV7hR{Bi[nWwZHHuZ4UhcW5idHjlJJRwfGGuIHPlcIwhdHm|YYTlJIFv\CCjdDD0bIUh[2WubDDzeZJn[WOn MoTvNlU4QDdyN{m=
TE13 Mn63SpVv[3Srb36gRZN{[Xl? MV[wMlPPxE1? MYiyOIg> NUHXXIZVfXBvcnXneYxifGW|IGLBV3NHPUFibHX2[Yw> Mn7QNlU2Pzl4NkW=
TE13 NFnTcGdCeG:ydH;zbZMhSXO|YYm= M4S1RVAvO87:TR?= M{TkO|I1cA>? M2j1VIlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25? MoS3NlU2Pzl4NkW=
MEFs MYDGeY5kfGmxbjDBd5NigQ>? MlfPOe69VQ>? M4HYXVE3cA>? NFrrOZZqdmO{ZXHz[ZMhfGinIFXQSWMh[XS2YXPocYVvfCxiVHnyJIRmdGm4ZYL5JIFv\CC2aHWg[YZncWOrZX7jfUBw\iCyZXTld5RidCCob4LtZZRqd25? MXeyOVQ5OjZ|NB?=
SW480  NXLkWpU5TnWwY4Tpc44hSXO|YYm= MWCwMlHPxE1? MXS0PIg> NUDwRnMyTE2VTx?= MmrIdoV3\XK|ZYOgSW1V NX\GXHlXOjV2M{S5PVc>
PC3  MXzGeY5kfGmxbjDBd5NigQ>? MYiwMlHPxE1? NWH1dlZJPDiq MkTxSG1UVw>? NYjQemVHemW4ZYLz[ZMhTU2W MnTLNlU1OzR7OUe=
SW480  MVHGeY5kfGmxbjDBd5NigQ>? NXn1SmQ2OC5zzszN NVvleXJFPDiq NUDDbpc4TE2VTx?= NETGN5difHSnboXheIV{KGmwdnHzbY9vKGGwZDDtbYdz[XSrb36= MnHpNlU1OzR7OUe=
PC3  NEDKZWlHfW6ldHnvckBCe3OjeR?= NY\uTYdkOC5zzszN M2jG[|Q5cA>? NFvzRY9FVVOR NEf6TY9ifHSnboXheIV{KGmwdnHzbY9vKGGwZDDtbYdz[XSrb36= M{O0SVI2PDN2OUm3
SW480  MVXGeY5kfGmxbjDBd5NigQ>? MoPrNE4y|ryP MX[0PIg> Mke3SG1UVw>? MV7pcoR2[2W|IHnuZ5Jm[XOnIH;mJGhFSUNzIHHu[EBJTEGFMjDvckBUdHWpIHflcoV{KHC{b33veIVz M2iwSVI2PDN2OUm3
PC3  Mnv4SpVv[3Srb36gRZN{[Xl? NWDvOVJpOC5zzszN MkXhOFhp NF\ObFdFVVOR NXu1[YkxcW6mdXPld{BqdmO{ZXHz[UBw\iCKRFHDNUBidmRiSFTBR|Ihd25iU3z1[{Bo\W6nczDwdo9ud3Snch?= Mon6NlU1OzR7OUe=
A431 M4TpWWFxd3C2b4Ppd{BCe3OjeR?= M3[3XFIwOTBxNUCvNVAxdk1? M136[FQ5cA>? MoXWSG1UVw>? NV;4R3VLcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4To MWSyOVM4OTB4OR?=
A431 NXSxOW1DTnWwY4Tpc44hSXO|YYm= NWjDelhOPTCwTR?= MUOyM|YwOTJxMkTo NULEZ2lNTE2VTx?= Mn61ZYN1cX[jdHXzJJAzOSCjbnSgbY5pcWKrdIOgRXRHOyCneIDy[ZN{cW:w M4HX[lI2OzdzME[5
MDA-MB-231 MlLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrFT3ExNTZyMH7N MnnSNlRp M1vKR2ROW09? M3vW[2lEPTBib3[gNVAxdk1? Mn7jNlUyQTJ5MkG=
MCF7 MoS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjZUWUxOC14MEDuUS=> MoTKNlRp NHrKOo1FVVOR M1m2fmlEPTBib3[gO|VvVQ>? MYiyOVE6Ojd{MR?=
SKOV-3 MnrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\HS5MyNTFyzszN M17HeVI1cA>? NUCw[JV[TE2VTx?= NXPY[YlJUUN3MDDv[kA2NjcQvF2= NHHUVZozPTF4OUS5NS=>
A549 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXEXZQ4OS1zMN88US=> M3\vT|I1cA>? NHTxc4lFVVOR M1jQT2lEPTBib3[gN{4z|ryP NGjqZVUzPTF4OUS5NS=>
SKOV-3 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljENE4yNTIQvF2= M4L4dVQ5cA>? NUi3VJlqTE2VTx?= MonoTWM2OCCxZjCwMlfPxE1? M2G4cVI2OTZ7NEmx
A549 NHjrTopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rOWFAvOS1zzszN Ml;YOFhp NYfZXXdETE2VTx?= NYqwVY5rUUN3MDDv[kAxNjJ6zszN NVTNXodiOjVzNkm0PVE>
SKOV-3 M3nt[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUSwMlAyNTBwOd88US=> MoXhO|Jp MYXEUXNQ NIrKdYFKSzVyIH;mJFAvOzMQvF2= NX7xZWc{OjVzNkm0PVE>
A549 NF7J[FlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TVTFAvODFvMD65{txO NXTKNmhyPzKq NF3URmpFVVOR M4D2TGlEPTBib3[gNE4xPs7:TR?= MYKyOVE3QTR7MR?=
HeLa M1LnWGZ2dmO2aX;uJGF{e2G7 NIXvPIMzPTCwTR?= MYOxOog> NFz6RZJFVVOR M1nPOYlv[3KnYYPld{BEYVBzQUGgcXJPSSCneIDy[ZN{cW:wwrC= NULuRoZuOjVzMU[2PFg>
CNE2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLse|EyODBvNkCwcm0> NH7WRWYzPC92OD:3Nog> MX3pcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MmXpNlQ6Pjl7MEG=
PC3 NVv2ell7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\kclExOC1zMECwcm0> Ml6xNlRp NGrCV5hKSzVyIH;mJFMxOG6P NGixN|czPDh3NE[1PC=>
LNCaP MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPlNVAxNTFyMEDuUS=> M3XqWFI1cA>? M{DKPWlEPTBib3[gN|Axdk1? NX3QeJlFOjR6NUS2OVg>
HeLa  M{\3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVq0Xo5KOs7:TR?= M1foeVQ5cA>? MmrF[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHHic5V1KDJ3JR?= NYTsSZZUOjR6NE[xN|U>
HMEC-1  MUDGeY5kfGmxbjDBd5NigQ>? NXP6c5B5OzBybl2= NXHKd4NmOjSq MmH1bY5kemWjc3XzJIV5eHKnc4Ppc44hd2cEoG\FS2ZTO8LibWLORS=> Mlv6NlQ4OTB4M{G=
HeLa MVTGeY5kfGmxbjDBd5NigQ>? MX:xcW0> MWOwMlVp NFLDXIFi[m:uaYPo[ZMhfGinIITveIFtKEiGQVOgZYN1cX[rdIm= MlTiNlQ4ODd2N{S=
ACP02 M33O[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmT6NlUxNzN3MD:1NFBvVQ>? MX6yOIg> MXfk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlib3[gZZBxem:6aX3heIVtgSB5MNMgKUBifCB{NUFCpI5O MlzBNlQ3Pjh3NEe=
ACP03 NGS2dJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fsOlI2OC9|NUCvOVAxdk1? NWHTVYpsOjSq NHm3b45l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgc4Yh[XCycn;4bY1ifGWueTC3NOKhLSCjdDCyOVDDqG6P MoDuNlQ3Pjh3NEe=
U87 GBM NGPJV2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HiflExOC9|MECvOVAxKG6P NW[y[HJCPzJiaB?= NF\4XJcyODBnIHX0bIFvd2x? MUDy[YR2[2W|IH3lZY4h[2WubDDueY1j\XJiYomgN|EtKDV2LDDhcoQhPTkEoDW= MV2yOFQ3PDh2MR?=
U87 GBM MYnGeY5kfGmxbjDBd5NigQ>? M3\N[lExOC93MECgUo0> Mm\OOFghcA>? NFHxZZEyODBnIHX0bIFvd2x? NFq1OIxKdmS3Y3XzJHNmdmW|Y3XuZ4UuVGmtZTDBcJRmemG2aX;ud{BqdiCQdXPs[YFzKE2xcoDoc4xw\3l? NITPdogzPDR4NEi0NS=>
RPE MmjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXSwMlIwOC52L{CuPE8yKM7:TR?= MXqyOE81QC95MjDo MXjEUXNQ MYjpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDifUBk\WyuIHP5Z4xmKGG{cnXzeC=> MnnwNlQ1PTZ4MEK=
HT29  MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;LNVE5OCCwTR?= MnzlO|IhcA>? M2jreGlEPTBib3[gNVgxKG6P M4W5blI1OzZ6Mk[1
hMSCs MXvGeY5kfGmxbjDBd5NigQ>? MYG2MlI2KG6P MWOyOEBp NFz5WmhFVVOR MlnMd5Ri[mmuaYrld{BJcXO2b37lJGFk\XS7bHH0bY9vKGGwZDD0bIUhTXiycnXzd4lwdiCxZjDQcJVzcXCxdHXueEBI\W6ncx?= NVXmc3hnOjR|MUKzOVY>
Huh7  NHrqVnJHfW6ldHnvckBCe3OjeR?= M3nheVAvOS9yLkWvNU4xKM7:TR?= M{T5[lI1cA>? MV3zeZBxemW|c3XzJHlVUESFMjDn[Y5mKGW6cILld5Nqd25? NEi5OIQzPDJ4OU[3Ni=>
SKOV3 MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYCwMlA2NTJizszN MVixNE8zPC92ODDo M2jSbGROW09? NETYcFFu\WSrYYTld{Boem:5dHigZZJz\XO2IHnuJIEh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NGP4UIMzPDJ{M{iwNS=>
A2780 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWiwMlA2NTJizszN NG\t[5QyOC9{ND:0PEBp Mm\YSG1UVw>? M3z5TI1m\GmjdHXzJIdzd3e2aDDhdpJme3RiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ MXiyOFIzOzhyMR?=
SRA01/04  NXvyXnVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\T[3B[OC5{IN88US=> Mn:1OFghcA>? MnG3SG1UVw>? MVnzeZBxemW|c3XzJINmdGxicILvcIln\XKjdHnvckB1cHKxdXfoJJN2eHC{ZYPzbY5oKHSqZTDQTVNMN0GtdDygdFM5VUGSSzDhcoQhTVKNMT:yJJNq\26jbHnu[{Bx[XSqd3H5dy=> MVWyOFE2Pzh5OB?=
HLEB3 M3XuPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3VZXExNjJizszN MYi0PEBp NF7Lb4VFVVOR M3PUXJN2eHC{ZYPz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKHSqcn;1[4ghe3WycILld5NqdmdidHjlJHBKO0txQXv0MEBxOziPQWDLJIFv\CCHUluxM|Ihe2mpbnHsbY5oKHCjdHj3ZZl{ MVWyOFE2Pzh5OB?=
SRA01/04  NF7RRWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nVSlAvPC9yLkig{txO M3LlOVQ5KGh? NHrkfIZFVVOR M3vEXolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M1u3W|I1OTV5OEe4
HLEB3 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXGwMlQwOC56IN88US=> MUW0PEBp M3;5UWROW09? MnLTbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NYXrSY5WOjRzNUe4O|g>
HCT116 NXXoWFJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY[wMlIh|ryP MXexNkBp NVH4e2NC\W6qYX7j[ZMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBz[WSrYYTpc44> M1O3dVI1OTJ{MkOx
CA46 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVSzM|YwOTJxMkSvOFghdk1? MV:0PEBp MlfHbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCjdDCyOEBidmRiNEigcm3DqA>? NFj2Vo0zPDB4NEm1NS=>
PMNs NWjR[IZbTnWwY4Tpc44hSXO|YYm= M4PmT|MxKG6P NHzuSo41QCCq M3\XUYlvcGmkaYTzJIVn\mW{b3P5eI9{cXNuIFjERWMh[WO2aY\peJkh[W6mIGLhZ{Bi[3Srdnn0fS=> M1\iUlI{QTh6NkG3
H1299 NXftUWZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LxbFHDqM7:TdMg M{nEZVI1NzR6L{eyJIg> M{G4cYV1cGGwb3y= Mo\QbY5kemWjc3XzJINmdGxiZHXheIgh[W[2ZYKgNlRp MWqyN|kyPjZyOR?=
A549 NVfsNm9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33iS|AvOjVxMD61M|Eh|ryP M2\E[|I1NzR6L{eyJIg> NXXjV2Ft\XSqYX7vcC=> MXvpcohq[mm2czD0bIUh[2WubDDndo94fGhiaX6gZ49v[2WwdILheIlwdiCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz NFXpWW0zOzh4N{m5NS=>
H1299 M37qOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PmTFAvOjVxMD61M|Eh|ryP NEfSSHQzPC92OD:3NkBp Mk\3[ZRp[W6xbB?= NInRdVhqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY4h[2:wY3XueJJifGmxbjDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NHexbVczOzh4N{m5NS=>
A549 NEi1ZlRCeG:ydH;zbZMhSXO|YYm= NEjrO5UxNjVxMTFOwG0> NWTV[XRNPDhiaB?= MULleIhidm:u NF31eGRqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NVr3VYEyOjN6Nke5PVE>
H1299 M1rEbWFxd3C2b4Ppd{BCe3OjeR?= NEC3RY4xNjVxMTFOwG0> MWS0PEBp NXv4Umln\XSqYX7vcC=> NXe1[oR3cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NEnuTlAzOzh4N{m5NS=>
SUM149PT MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nmUFIwPy53L{GwJO69VQ>? MWe0PEBp MkHRSG1UVw>? NITRWYdqdmS3Y3XzJINmdGxiZHXheIgh[XRiMjFOwG0hcW6|ZX7zbZRqfmWueR?= Mn;0NlM4QTJ4M{i=
SUM190PT NFPiR2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LYRVUxNzFyMD:yOVAhdk1? MlO0OFghcA>? NGTVRnZFVVOR NV[wbmQycW6mdXPld{Bk\WyuIHTlZZRpKGG2IEWwJI5OKHOnboPpeIl3\Wy7 NUf0e|I4OjN5OUK2N|g>
HCT1 MnGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWewMlIwOS5yL{WuNEDPxE1? MkToNVIwOjRxM{[vOFghcA>? M3fjbIlv\HWlZYOgZ4VtdCCmZXH0bEBqdiClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy M{K2fVI{PzdyMECw
Lovo M13WeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUGwMlIwOS5yL{WuNEDPxE1? Ml\0NVIwOjRxM{[vOFghcA>? MXnpcoR2[2W|IHPlcIwh\GWjdHigbY4h[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MYSyN|c4ODByMB?=
AGS NGezWYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NImwOIgxNjBzNT2xJO69VQ>? NHLzOXI4OiCq NXHIb3hScW6mdXPld{Bk\WyuIHTlZZRpKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk> M4PCOFI{PzR3MEK0
Huh7 MkfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\vWlEh|ryP NWi4O3UyOjRiaB?= MYfEUXNQ M{PvbJJm\HWlZYOgZYJwfXRiMkClJJZq[WKrbHn0feKh MlzYNlM3PDN7M{O=
ECC1 Mo\RSpVv[3Srb36gRZN{[Xl? MWW1NFAhdk1? M4Xqe|Uh\A>? NHrxWGNFVVOR M1e1fIlv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF MkHwNlM2OzB5Nkm=
HEC1A M4TGU2Z2dmO2aX;uJGF{e2G7 NWHqdYdGPTByIH7N NWj4OZNRPSCm MnvXSG1UVw>? Mne3bY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? MYCyN|U{ODd4OR?=
EN1 NEOyWWRHfW6ldHnvckBCe3OjeR?= Mo\3OVAxKG6P M{O4cFUh\A>? M1LDTGROW09? Ml7ubY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? MnjzNlM2OzB5Nkm=
MFE296 NWTSTWs1TnWwY4Tpc44hSXO|YYm= Mn6yOVAxKG6P MWe1JIQ> M37teGROW09? M4\Gb4lv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF NUWyOHhxOjN3M{C3Olk>
HASMCs M4iyNGZ2dmO2aX;uJGF{e2G7 NYLLb21wOC13MECgcm0> MWG2JIQ> NF;hRVJld3ewLYLl[5Vt[XSnczD0bIUh\XiycnXzd4lwdiCxZjDIRWREKGGwZDDj[YxtKH[rYXLpcIl1gQ>? NITNNGMzOzVzOES2Oy=>
U373 MYjGeY5kfGmxbjDBd5NigQ>? NWm2XVJWOC5{NT:wMlUwOSEQvF2= NE\Y[4wzPCCq NV7RT3o6cW6lcnXhd4V{KFCULVKg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2SXqjZFO= MXeyN|Q4PDF5MR?=
ARN8  NFr1O5RHfW6ldHnvckBCe3OjeR?= NX3lZ2ZNOC5yNT2yJO69VQ>? MmH3NlQhcA>? NULlVI16emWmdXPld{B1cGViaX7keYN1cW:wIH;mJJA2Oy2mZYDlcoRmdnRiZ3Xu[ZMh[nliToX0cIlvNTN? NFn0UmYzOzR5MEW0NC=>
MCF7 M3THfmZ2dmO2aX;uJGF{e2G7 NFLQVGIxNjB3LUKg{txO MVmyOEBp M4PMTJJm\HWlZYOgeIhmKGmwZIXjeIlwdiCxZjDwOVMu\GWyZX7k[Y51KGenbnXzJIJ6KE63dHzpck0{ NELhfHkzOzR5MEW0NC=>
H1299  NV7vd|BFTnWwY4Tpc44hSXO|YYm= NWXjOmlHOC5|M,MAl|HDqML3TR?= NXX5RmdHOjRxNEigbC=> NH2wTIFFVVOR MYrpcoNz\WG|ZYOgSU1k[WSqZYLpckBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7 NYnydIhHOjN2NkG5O|U>
H1299 NIXFPZBHfW6ldHnvckBCe3OjeR?= NUL3cGVjOC53IN88US=> NEnSV2I1QCCq M1XCSWROW09? MWXpcohq[mm2czD0bIUhdWmpcnH0c5J6KHCxdHXueIlidCClb33ibY5mKHerdHigd4ltcWKrbnnu NFm4OmszOzR4MUm3OS=>
H1299 M33CV2Z2dmO2aX;uJGF{e2G7 MXuwMlUh|ryP MVG0PEBp MUXEUXNQ NX7wO3U2cW6qaXLpeJMhfGinIHnueoF{cX[nbnXzd:KhKGOxbXLpcoUhf2m2aDDzbYxq[mmwaX6= M1iwfFI{PDZzOUe1
MG-63  NXTEZ5pHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;CRWtKOC5|IN88US=> MU[xNk06PiCq NFzxNYdFVVOR MmTHbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHPvMZRz\WG2bXXueEB4cXSqIH3leIZwem2rbh?= NHT3SZIzOzR3MUixOy=>
LM8 NYXsOVBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\rWnAxNjNizszN MWmxNk06PiCq NUTuSmI4TE2VTx?= MYjpcohq[mm2czD0bIUh[2WubDDndo94fGhiY3:teJJm[XSvZX70JJdqfGhibXX0[o9zdWmw MorlNlM1PTF6MUe=
K562 MkPXSpVv[3Srb36gRZN{[Xl? NI\iXWwxNjVizszN MVeyOEBp MorF[ZRp[W6xbB?= NEDnWHhl\WO{ZXHz[ZMhfGinIHXufplu\SCjY4Tpeol1gSCxZjDISGFEeyClbz30doVifG2nboSge4l1cCCldYLjeY1qdg>? NXHJPVFHOjN2M{C5OVc>
HEL NIf1eI5HfW6ldHnvckBCe3OjeR?= MkGwNE42KM7:TR?= NVfOWoZOOjRiaB?= M2DLcYV1cGGwb3y= NV75b4p{\GWlcnXhd4V{KHSqZTDlcpp6dWViYXP0bZZqfHlib3[gTGRCS3NiY3:teJJm[XSvZX70JJdqfGhiY4XyZ5VucW5? M{LwdlI{PDNyOUW3
HL60 MYTBdI9xfG:|aYOgRZN{[Xl? M4\vT|Eh|ryP MVOyOEBp NEDqO2hqdmS3Y3XzxsBk\WyuIHTlZZRp MVqyN|QxODVzOR?=
KG1 MnHpRZBweHSxc3nzJGF{e2G7 NUKyW2tbOSEQvF2= NFXWSHQzPCCq M1;pU4lv\HWlZYRCpINmdGxiZHXheIg> MkO1NlM1ODB3MUm=
Kazumi NYq1WmhXSXCxcITvd4l{KEG|c3H5 MlvRNUDPxE1? M{WxUlI1KGh? NHvZdplqdmS3Y3XzxsBk\WyuIHTlZZRp MXeyN|QxODVzOR?=
K562 M3[xd2Fxd3C2b4Ppd{BCe3OjeR?= MlXFNUDPxE1? NHXtVYIzPCCq MV7pcoR2[2W|wrDj[YxtKGSnYYTo NXzueXc{OjN2MEC1NVk>
THP1 NHzNNGVCeG:ydH;zbZMhSXO|YYm= MVGxJO69VQ>? NUH2RYRyOjRiaB?= NGXMOo5qdmS3Y3XzxsBk\WyuIHTlZZRp MUOyN|QxODVzOR?=
SH-SY5Y NXnjcGYxTnWwY4Tpc44hSXO|YYm= M1m3eVI2OCCwTR?= M13jXVE3KGh? MkXBZ4hidmenczDlfJBz\XO|aX;uJJBifHSncn6gc4Yh\2WwZYOgbY53d2y4ZXSgbY4h[2ixbHXzeIVzd2xic4nueIhme2m|LDD1dJRic2ViYX7kJIVn\my3eB?= NXHpU4FsOjN|Mk[0NlI>
HEK293 MoLPSpVv[3Srb36gRZN{[Xl? NIrSUmMyKML3TdMg M3S3T|E5KGkEoB?= Mn:5bY5pcWKrdIOgeIhmKGujbHnybY4uPy2vZXTpZZRm\CC{ZXPyeYl1dWWwdDDv[kB{gW6yaHnsbY4uOSCjZ3fy[YdifGW|IHnueI8h[WepcnXzc41mew>? M1jkU|I{Ojh2OES4
HTK MoLySpVv[3Srb36gRZN{[Xl? Mn;YOFAxKG6P M2\vO|czKGh? M3LnNIlvcGmkaYTzJHRITi4QsvMAl2lv\HWlZXSgUZlw\mmkcn;icIF{fCCGaX\m[ZJmdnSrYYTpc44> NFPKcmgzOzJ6NECwNi=>
HTK M{TV[GZ2dmO2aX;uJGF{e2G7 NFvwW|YyODBvOECwcm0> M{DzfFczKGh? NETQ[IVjdG:la4OgWGdHNc7{4pETTY5lfWOnZDDSU3Mh[W6mIFiyU|LDqEGlY4XteYxifGmxbh?= MnOxNlMzQDRyMEK=
Caco-2  MWPGeY5kfGmxbjDBd5NigQ>? MV6xJOK2VcLi Ml76NlQhcA>? M4XwbYRm[3KnYYPld{BUTVKWIIDyc5RmcW5iZYjwdoV{e2mxbh?= MYqyN|E6PTB5MB?=
HeLa MoH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\mNVAxKG6P NF\G[FAzPCCq NIDVd2NFVVOR M1HUVmlEPTBib3[gNVAxdk1? M17yfVI{OTZ3N{S4
HeLa NHj0WlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjhTYVWPDBibl2= M1racVQ5KGh? M4DVT2ROW09? NGC5NopKSzVyIH;mJFQxdk1? NXG2eJZ6OjNzNkW3OFg>
HeLa NF;kPHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzlNlAhdk1? NFHHWYI4OiCq NV6xXlRQTE2VTx?= NX\rN2Y2UUN3MDDv[kAzOG6P M{jxbVI{OTZ3N{S4
HeLa NWDEUpdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPUNVAwOzBxNUCgcm0> M{TUZ|czKGh? NWTEOWJwTE2VTx?= MWfpcoNz\WG|ZYOgeIhmKG63bXLldkBw\iCPTWCgLO6V|qivKTDsc5N{KGOnbHzzJIRwe2ViZHXw[Y5l\W62bIm= M2CxflI{OTZ3N{S4
MDA-MB-231 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoryNlUuPDByIH7N NUDBR4t1PDhiaB?= MYPJR|UxKG:oIEK2N{4zdk4EoB?= NXXMeWo6OjNyNUWxPVg>
MCF-7  NXS1UndvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXnNlUuPDByIH7N NHvBOI81QCCq M{TOW2lEPTBib3[gNlIxNjSwTR?= MWOyN|A2PTF7OB?=
ECC-1  Ml\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHO4c|AyODBibl2= M4\BcFI1KGh? NY\DNIl5\XSqYX7vcC=> M1zDOolv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBieG:ydH;0bYMhdnWlbHXpJJRwKDN3JR?= Moi2NlMxOjh6MEO=
HEC-1A NYP2TIdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYSxNFAhdk1? Ml7JNlQhcA>? NUDnS45m\XSqYX7vcC=> MWLpcoNz\WG|ZYOgeIhmKHC{b4DvdpRqd25ib3[gZZBweHSxdHnjJI52[2ynaTD0c{A{QSV? M{\nWVI{ODJ6OECz
NHAC-kn MoTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnvO2lFOTBxMUCwM|UxOCCwTR?= MojONVIhcA>? NH3FZ2dFVVOR NXfmXHhUUUN3MDDv[kA2ODCwTR?= MV6yN|AyPzh5MR?=
A549 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzuNlUxKG6P NUPiVVF7Pi15MjDo Mlu0SG1UVw>? MlLjZ4F2e2W|IHGg[5Jm[XSncjDpcohq[mm2b4L5JIVn\mWldDDjc41jcW6nIIfpeIghXFiWIH;yJIVzdG:2aX7pZi=> M{\RblIzQTl2N{iw
MG-63 M1n2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLEN|AxKG6P NYjR[XBXOTJiaB?= NFfvNI5FVVOR NV75O5gxcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDh4JR?= NHnmdFgzOjd7OUOzPC=>
MG-63 M2DlOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV6zNFAhdk1? NYjVXFJEOjRiaB?= NFj4WHRFVVOR MWPpcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gOlcm MnPBNlI4QTl|M{i=
MG-63 NYD5VVZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmryN|AxKG6P NYrPelFsPDhiaB?= NU\tS2JyTE2VTx?= NGO2RmpqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPTZn MYeyNlc6QTN|OB?=
HL60  MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHwNVUxNTN3MDDuUS=> MlnONlQhcA>? M3fNSIlv[3KnYYPld{Bk\WyuIHHwc5B1d3Orc9Mge4hmdiClb37j[Y51emG2aX;ud{BpcWeqZYKgeIhidiB{NUCgcm0> MlzBNlI4PTN5M{m=
U937 M2qxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfN[oVSOTVyLUO1NEBvVQ>? NEi1XYczPCCq MYDpcoNz\WG|ZYOgZ4VtdCCjcH;weI9{cXQEoIfo[Y4h[2:wY3XueJJifGmxboOgbIlocGW{IIToZY4hOjVyIH7N MnLTNlI4PTN5M{m=
SCC-6 NFXhOpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrBb2UzODBvM{KwNEBvVQ>? MnPoNVIwOjRxNEigbC=> MkfXSG1UVw>? NIfsdVZqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBw\iCVQ1OtOkBk\WyuczDpckBiKGSxc3WtJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= MVqyNlU2OjN{MR?=
U87  MoKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1SyNlExOC1|MECgcoc> MnX6NlQhcA>? NF65bWhqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPzJnIDDheEAzODCwZx?= NFH0WVQzOjJ5MEi0PS=>
K562 MUXGeY5kfGmxbjDBd5NigQ>? NIK3OY8yKM7:TR?= M3rjRlEzKGh? Ml3RSG1UVw>? MoPU[Y5p[W6lZYOgeIhmKGW6cILld5Nqd25ib3[gVnVPYDNiaX7keYNm\CCkeTC1MYF7[S2FZGK= NWLZZ2RrOjJzN{mxPVg>
Reh MljwSpVv[3Srb36gRZN{[Xl? NGjORpkxNjNxMTFOwG0> MnP6NVIhcA>? MXXEUXNQ Ml\1[Y5p[W6lZYOgeIhmKGW6cILld5Nqd25ib3[gVnVPYDNiaX7keYNm\CCkeTC1MYF7[S2FZGK= MV2yNlE4QTF7OB?=

... Click to View More Cell Line Experimental Data

In vivo Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research:

[1]

+ Expand
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM
  • Incubation Time: 96 hours
  • Method:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • Formulation: Dissolved in DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: Injection s.c.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
1% DMSO+30% polyethylene glycol+1% Tween 80, pH 4
6 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 302.4
Formula

C17H22N2O3

CAS No. 58880-19-6
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02959905 Recruiting Metastatic Melanoma BGI, China|Sun Yat-sen University December 2016 Phase 1
NCT02486965 Recruiting Fibromyalgia University Hospital, Brest October 2015 --
NCT01954433 Recruiting Glenohumeral Arthritis and/or Rotator Cuff Tear Arthropathy (TSA)|Rotator Cuff Tear (RCR)|Trapeziometacarpal Osteoarthritis (TMC OA) Matthias Flury|Winterthur Institute of Health Economics (WIG), Switzerland|Schulthess Klinik November 2013 --
NCT01575106 Unknown status Pain Massachusetts General Hospital June 2012 --
NCT02762903 Completed Osteoarthritis Columbia University August 2009 --
NCT00914173 Completed Pain Medasense Biometrics Ltd November 2008 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • Answer:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Trichostatin A (TSA) | Trichostatin A (TSA) supplier | purchase Trichostatin A (TSA) | Trichostatin A (TSA) cost | Trichostatin A (TSA) manufacturer | order Trichostatin A (TSA) | Trichostatin A (TSA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID